# Cytek Biosciences (CTKB) — Earnings

CTKB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ctkb/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.09 |
| EPS estimate | −$0.09 |
| EPS surprise | +3.54% |
| Revenue surprise | +1.76% |
| Revenue | $48.1M |
| Revenue estimate | $47.3M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1831915/000162828026053496/ctkb-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/60d441c4-8ce2-6047-ab91-4a2557114982.html) |

Cytek Biosciences reported Q2 2026 results on August 5, 2026, posting a loss of $0.09 per share. That matched the rounded $0.09 loss estimate, a 3.54% beat on the table's surprise figure. Revenue of $48.1 million topped the $47.3 million consensus by 1.76%. Compared with Q2 2025, revenue grew about 5% from $45.6 million, while the loss widened from $0.04 per share.

Cytek has moved from small profits into losses. Annual EPS was $0.14 in 2022, $0.09 in 2023 and $0.14 in 2024, then a loss of $0.47 in 2025. Q4 2025's loss of $0.34 per share is the largest in the table, and Q4 2024's $0.12 profit is the highest. Revenue grew from $164.1 million in 2022 to $193.4 million in 2023, then flattened at $200.5 million in 2024 and $201.5 million in 2025. The first half of 2026 shows a loss of $0.24 per share, against $0.13 a year earlier, on revenue about 6% higher.

Q3 results arrived between November 5 and November 9 in each of the past five years. That points to early November 2026, when the report will show whether revenue growth continues and how the result compares with break-even in Q3 2025.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.09 | −$0.09 | 3.54% | $47.3M | $48.1M |
| Q1 2026 | May 7, 2026 | −$0.09 | −$0.15 | -62.16% | $44.2M | $44.1M |
| Q4 2025 | Feb 26, 2026 | −$0.02 | −$0.34 | -1600.00% | $57.1M | $62.1M |
| Q3 2025 | Nov 5, 2025 | −$0.03 | $0.00 | 114.00% | $51.2M | $52.3M |
| Q2 2025 | Aug 6, 2025 | −$0.05 | −$0.04 | 16.67% | $46.3M | $45.6M |
| Q1 2025 | May 8, 2025 | −$0.03 | −$0.09 | -172.73% | $42.7M | $41.5M |
| Q4 2024 | Feb 27, 2025 | $0.10 | $0.12 | 17.74% | $59.4M | $57.5M |
| Q3 2024 | Nov 5, 2024 | $0.01 | $0.06 | 448.70% | $50.7M | $51.5M |
| Q2 2024 | Aug 6, 2024 | −$0.00 | −$0.03 | -782.76% | $49.5M | $46.6M |
| Q1 2024 | May 8, 2024 | −$0.03 | −$0.01 | 72.40% | $43.6M | $44.9M |
| Q4 2023 | Mar 1, 2024 | $0.03 | $0.09 | 200.00% | $56.6M | $58.6M |
| Q3 2023 | Nov 7, 2023 | $0.02 | −$0.01 | -135.00% | $55.5M | $48.0M |
| Q2 2023 | Aug 8, 2023 | $0.01 | $0.01 | 15.00% | $45.7M | $49.7M |
| Q1 2023 | May 9, 2023 | $0.02 | $0.00 | -100.00% | $47.1M | $37.1M |
| Q4 2022 | Feb 28, 2023 | $0.04 | $0.06 | 41.18% | $50.2M | $48.3M |
| Q3 2022 | Nov 9, 2022 | $0.01 | $0.04 | 220.00% | $43.3M | $40.5M |
| Q2 2022 | Aug 10, 2022 | $0.01 | $0.03 | 140.00% | $39.6M | $40.2M |
| Q1 2022 | May 11, 2022 | −$0.01 | $0.01 | 200.00% | $32.5M | $35.1M |
| Q4 2021 | Feb 23, 2022 | $0.03 | $0.00 | -100.00% | $36.4M | $38.9M |
| Q3 2021 | Nov 8, 2021 | $0.02 | $0.02 | -14.16% | $33.4M | $34.4M |

## Frequently Asked Questions

### When did Cytek Biosciences (CTKB) last report earnings?

Cytek Biosciences last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did CTKB beat earnings estimates?

Yes. Cytek Biosciences reported EPS of −$0.09 for Q2 2026 against a −$0.09 estimate — a 3.54% beat.

### How much revenue did CTKB report last quarter?

Cytek Biosciences reported $48.1M in revenue for Q2 2026, against a consensus estimate of $47.3M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).